Roche: have abandoned some trials due to U.S. drug pricing plans
FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration because of planned price cuts in best-selling prescription medicines in the United States. Speaking in a media call after the release of first-half results, CEO Thomas Schinecker said the Swiss group was not taking the lead on any legal action…
